You are here

Article Text

Article menu
Download PDFPDF
LETTER
A pilot study in patients with established advanced liver fibrosis using pirfenidone
  1. J Armendáriz-Borunda1,
  2. M C Islas-Carbajal2,
  3. E Meza-García2,
  4. A R Rincón3,
  5. S Lucano4,
  6. A S Sandoval4,
  7. A Salazar4,
  8. J Berumen5,
  9. A Alvarez6,
  10. A Covarrubias7,
  11. G Aréchiga8,
  12. L García8
  1. 1Institute for Molecular Biology in Medicine and Gene Therapy, Guadalajara, Jalisco, México, and OPD Civil Hospital of Guadalajara, Guadalajara, Jalisco
  2. 2Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Jalisco, México
  3. 3Institute of Chronic Degenerative Diseases, Guadalajara, Jalisco, México
  4. 4Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Jalisco, México
  5. 5Unit of Genomic Medicine, General Hospital of México, México
  6. 6Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Jalisco, México
  7. 7OPD Civil Hospital of Guadalajara, Guadalajara, Jalisco, México
  8. 8Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Jalisco, México
  1. Correspondence to:
    Dr J Armendáriz-Borunda
    Institute for Molecular Biology in Medicine and Gene Therapy, Apdo Postal 2-123, Guadalajara, Jalisco, México 44281; armendbo{at}cucs.udg.mx

https://doi.org/10.1136/gut.2006.107136

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Cirrhosis represents the third cause of mortality among Mexican people of productive age.1 Several drugs have been tested in the clinical scenario2,3 although conclusive evidence concerning drug efficacy has proven elusive.

    PFD is an orally bioavailable pyridone derivative (5-methyl-1-phenyl-2-(1H)-pyridone) that affects a variety of profibrogenic cytokines and its mechanism of action mostly resides in its anti-inflammatory and antifibrotic activity.4–,6 Here we present data obtained from a pilot clinical trial evaluating the safety and efficacy of PFD in 15 patients with established advanced liver disease caused by hepatitis C virus chronic infection. This is the first report showing improvements in liver histology (that is, necrosis, inflammation, steatosis, fibrosis, and cell regeneration) 12 months after PFD therapy. Colour Doppler ultrasound guided liver biopsies were obtained at baseline and after 12 months of PFD treatment and evaluated for stage of fibrosis and grade of activity according to the modified …

    View Full Text

    Footnotes

    • Conflict of interest: None declared.